OTCMKTS:ICOTF - iCo Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.0627 0.00 (-1.42 %) (As of 03/21/2019 04:08 AM ET)Previous Close$0.0636Today's Range$0.0627 - $0.062752-Week Range$0.0209 - $0.2035Volume10,000 shsAverage Volume14,996 shsMarket Capitalization$6.86 millionP/E RatioN/ADividend YieldN/ABeta2.16 ProfileDiscussionChartEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections. The company was founded in 2005 and is headquartered in Vancouver, Canada. Receive ICOTF News and Ratings via Email Sign-up to receive the latest news and ratings for ICOTF and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ICOTF Previous Symbol CUSIPN/A CIKN/A Webwww.icotherapeutics.com Phone778-802-9806Debt Debt-to-Equity RatioN/A Current Ratio1.06 Quick Ratio1.06Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book6.27Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-950,000.00 Net MarginsN/A Return on Equity-201.81% Return on Assets-133.62%Miscellaneous EmployeesN/A Outstanding Shares109,458,000Market Cap$6.86 million Next Earnings Date4/23/2019 (Estimated) OptionableNot Optionable iCo Therapeutics (OTCMKTS:ICOTF) Frequently Asked Questions What is iCo Therapeutics' stock symbol? iCo Therapeutics trades on the OTCMKTS under the ticker symbol "ICOTF." When is iCo Therapeutics' next earnings date? iCo Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, April 23rd 2019. View Earnings Estimates for iCo Therapeutics. Has iCo Therapeutics been receiving favorable news coverage? News stories about ICOTF stock have been trending very negative this week, InfoTrie reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. iCo Therapeutics earned a news impact score of -3.6 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. Who are some of iCo Therapeutics' key competitors? Some companies that are related to iCo Therapeutics include Aileron Therapeutics (ALRN), Novan (NOVN), ContraFect (CFRX), Q BioMed (QBIO), Adial Pharmaceuticals (ADIL), Heat Biologics (HTBX), Acerus Pharmaceuticals (TRLPF), Citius Pharmaceuticals (CTXR), Evoke Pharma (EVOK), IMMURON LTD/S (IMRN), SUMMIT THERAPEU/S (SMMT), RegeneRx Biopharmaceuticals (RGRX), Onconova Therapeutics (ONTX), MOTIF BIO PLC/S (MTFB) and Ceapro (CRPOF). What other stocks do shareholders of iCo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other iCo Therapeutics investors own include United States Brent Oil Fund (BNO), National Bank of Canada (NA), Velocity Data (VCT), AAR (AIR), Lendlease Group (LLC), Constellation Brands (STZ), Mid-America Apartment Communities (MAA), iShares Transportation Average ETF (IYT), ABM Industries (ABM) and American River Bankshares (AMRB). Who are iCo Therapeutics' key executives? iCo Therapeutics' management team includes the folowing people: Mr. Andrew J. Rae M.B.A., BSc, MBA, Co-Founder, CEO, Pres & Director (Age 52)Mr. Michael Liggett CPA, CA, Bsc. Pharm., CFO, Corp. Sec. & Director (Age 59)Dr. Peter Hnik M.D., MHSc, Chief Medical Officer (Age 63) How do I buy shares of iCo Therapeutics? Shares of ICOTF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is iCo Therapeutics' stock price today? One share of ICOTF stock can currently be purchased for approximately $0.0627. How big of a company is iCo Therapeutics? iCo Therapeutics has a market capitalization of $6.86 million. What is iCo Therapeutics' official website? The official website for iCo Therapeutics is http://www.icotherapeutics.com. How can I contact iCo Therapeutics? iCo Therapeutics' mailing address is 777 Hornby Street 6th Floor, Vancouver A1, V6Z 1S4. The biotechnology company can be reached via phone at 778-802-9806 or via email at [email protected] MarketBeat Community Rating for iCo Therapeutics (OTCMKTS ICOTF)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 50 (Vote Outperform)Underperform Votes: 45 (Vote Underperform)Total Votes: 95MarketBeat's community ratings are surveys of what our community members think about iCo Therapeutics and other stocks. Vote "Outperform" if you believe ICOTF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICOTF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/21/2019 by MarketBeat.com StaffFeatured Article: What are Institutional Investors?